Avidity Biosciences, Inc. RNA
Institutional shares held
100 Million
517K
calls
717K
puts
Total value of holdings
$2.67B
$13.8M
calls
$19.1M
puts
Market Cap
$1.39B
52,127,000
Shares Out.
Institutional ownership
192.23%
# of Institutions
258
We take great care to ensure that the data presented and summarized in this overview for Avidity Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RNA
View all-
Price T Rowe Associates Inc Baltimore, MD11MShares$294 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.43MShares$251 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$230 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.93MShares$211 Million3.76% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.5MShares$200 Million3.18% of portfolio
-
Janus Henderson Group PLC London, X07.05MShares$188 Million0.11% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.3MShares$168 Million2.97% of portfolio
-
State Street Corp Boston, MA4.6MShares$123 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.81MShares$74.8 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.75MShares$73.4 Million0.15% of portfolio
Latest Institutional Activity in RNA
Top Purchases
Top Sells
About RNA
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Insider Transactions at RNA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 01
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
5,875
-5.27%
|
$158,625
$27.83 P/Share
|
|
Apr 01
2025
|
Kathleen P. Gallagher Chief Program Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,875
+4.82%
|
$88,125
$15.68 P/Share
|
|
Mar 20
2025
|
W. Michael Flanagan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
11,780
-12.81%
|
$365,180
$31.06 P/Share
|
|
Mar 20
2025
|
Sarah Boyce President and CEO |
SELL
Open market or private sale
|
Direct |
31,540
-9.35%
|
$977,740
$31.06 P/Share
|
|
Mar 20
2025
|
Steven George Hughes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,578
-11.62%
|
$296,918
$31.06 P/Share
|
|
Mar 20
2025
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
7,778
-7.41%
|
$241,118
$31.06 P/Share
|
|
Mar 20
2025
|
Michael F Mac Lean Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,935
-7.58%
|
$245,985
$31.06 P/Share
|
|
Mar 11
2025
|
W. Michael Flanagan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,000
-17.86%
|
$600,000
$30.13 P/Share
|
|
Mar 11
2025
|
W. Michael Flanagan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+15.15%
|
$280,000
$14.22 P/Share
|
|
Mar 03
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
5,875
-10.41%
|
$170,375
$29.41 P/Share
|
|
Mar 03
2025
|
Kathleen P. Gallagher Chief Program Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,875
+9.43%
|
$82,250
$14.7 P/Share
|
|
Feb 03
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
5,875
-10.41%
|
$188,000
$32.16 P/Share
|
|
Feb 03
2025
|
Kathleen P. Gallagher Chief Program Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,875
+9.43%
|
$94,000
$16.65 P/Share
|
|
Jan 22
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
5,629
-10.02%
|
$168,870
$30.16 P/Share
|
|
Jan 21
2025
|
Michael F Mac Lean Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,287
-1.53%
|
$92,036
$28.59 P/Share
|
|
Jan 21
2025
|
Arthur A Levin Director |
SELL
Open market or private sale
|
Direct |
1,872
-12.62%
|
$52,416
$28.6 P/Share
|
|
Jan 21
2025
|
Sarah Boyce President and CEO |
SELL
Open market or private sale
|
Direct |
10,397
-1.51%
|
$291,116
$28.59 P/Share
|
|
Jan 21
2025
|
W. Michael Flanagan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,672
-2.94%
|
$158,816
$28.6 P/Share
|
|
Jan 21
2025
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
2,959
-1.38%
|
$82,852
$28.6 P/Share
|
|
Jan 21
2025
|
Steven George Hughes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,947
-2.31%
|
$110,516
$28.6 P/Share
|
Last 12 Months Summary
Buy / Acquisition
1.95M
Shares
From
17
Insiders
| Grant, award, or other acquisition | 873K shares |
|---|---|
| Exercise of conversion of derivative security | 1.05M shares |
| Bona fide gift | 22.5K shares |
Sell / Disposition
1.54M
Shares
From
9
Insiders
| Open market or private sale | 1.52M shares |
|---|---|
| Bona fide gift | 22.5K shares |